BAYER AG

Bayer submits sNDA to FDA for darolutamide in mHSPC, based on ARANOTE trial results. Darolutamide, co-developed by Orion and Bayer, is already approved in mHSPC and nmCRPC. Nubeqa sales exceeded €1 billion in 2024, marking a milestone for Orion.

MP Nigdelis received honoraria from RG Ärztefortbildung GmbH and travel grants from Organon and Gedeon Richter. M Doerk received travel grants from Gedeon Richter, Organon, and Eisai, and is a member of DGGG, AGE, and Deutsche Gesellschaft für Senologie. S Burghaus received honoraria from FOMF and is a member of DGGG, AGEM, AGE, Stiftung Endometriose Forschung, AGUB, AGO, and DKK. M Sillem, CEO of EuroEndoCert Gmbh, received payments from Bayer, Gedeon Richter, Hologic, and EndoHealth. B Haj Hamoud received travel grants from Gedeon Richter, Astrazeneca, Johnson & Johnson, and Storz, and is a member of DGGG, AGE, and Stiftung Endometriose Forschung. EF Solomayer receives grants from the University of Saarland, Storz, and Erbe, and fees from Roche, Pfizer, Celgene, Amgen, Astra Zeneca, Esai, Johnson & Johnson, Novartis, Tesaro, Teva, Medac GmbH, MSD, Vifor, Gedeon Richter, Takeda, and AGE, among others. GL Olmes received grants from AstraZeneca, Universitätsklinikum Freiburg, and RG Ärztefortbildung GmbH, and is a member of DGGG, AGE, and AGEM, with scientific collaboration with Karl Stotz.

US-based v-Fluence Interactive, funded by the US government, profiles critics of pesticides and GM crops globally, including in India, raising privacy concerns. The firm's private social network, Bonus Eventus, contains over 500 profiles, including those of Indian activists Vandana Shiva and Debal Deb. v-Fluence denies allegations of secret profiling and misuse of data, claiming all information is publicly available. The firm's activities have sparked debate on data protection and scientific integrity in India.

Bayer submits sNDA to FDA for darolutamide's third indication in mHSPC, based on ARANOTE trial results. Darolutamide, co-developed by Orion and Bayer, is already approved in mHSPC and nmCRPC, achieving blockbuster status with over €1 billion in sales.

The drug and biotech sector has outperformed the broader market, driven by new drug launches, pipeline successes, and increased M&A activity. Eli Lilly's obesity drugs have been particularly successful. Despite headwinds like pipeline setbacks and economic uncertainty, the sector has seen a surge in investments. Five large drugmakers—Pfizer, Eli Lilly, AstraZeneca, Bayer, and Sanofi—are recommended for portfolio growth, with strong financials and robust pipelines.

© ALM Global, LLC. All Rights Reserved. Logo of China Law And Practice.

Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

A West Virginia judge rejected a preliminary injunction preventing Amgen from launching a biosimilar of Regeneron's eye drug Eylea, causing Regeneron stock to tumble. The FDA approved Amgen's Pavblu, which could launch at risk while the companies are in court. Regeneron plans to appeal, noting the decision only applies to Amgen and the standard dose of Eylea. The court battle could impact Eylea's Medicare negotiations under the Inflation Reduction Act.

The agricultural biotechnology market is projected to grow from USD 111 billion in 2023 to USD 232 billion by 2033, driven by advancements in technology and sustainable practices. Innovations like biofertilizers, biopesticides, and genetic enhancements improve yields and reduce environmental impact. Key players include Corteva, BASF, and Bayer AG, with strategic developments focusing on gene editing and regenerative agriculture. The market faces challenges such as high costs and environmental concerns, but is essential for meeting global food demands.